The company
UroGen Pharma Ltd. -
URGN · Nasdaq
URGN stood above a rising 150-day average in 44 of the last 52 weekly readings, including each of the last 27 weeks. It is 2.2% above that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).
Statistics
- Rotation
- In trend
- Weeks in an uptrend
- 27 in a row
- Industry in uptrend
- 18% -14 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $9.2M
- Officials’ trades on record
- 0
- Institutions holding
- 182 (+19)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 44 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Chris DegnanChief Financial Officer | sold | 2,202at $36.69 | 8 Oct 2026filed 9 Oct 2026 |
| Jason Drew SmithGeneral Counsel | sold | 1,519at $42.54 | 8 Sep 2026filed 9 Sep 2026 |
| Mark SchoenbergChief Medical Officer | sold | 871at $42.92 | 8 Sep 2026filed 9 Sep 2026 |
| Mark SchoenbergChief Medical Officer | sold | 60,677at $47.05 | 20 Aug 2026filed 24 Aug 2026 |
| Mark SchoenbergChief Medical Officer | sold | 10,000at $40.00 | 9 Jul 2026filed 10 Jul 2026 |
| Mark SchoenbergChief Medical Officer | sold | 10,000at $35.01 | 22 Jun 2026filed 24 Jun 2026 |
| Mark SchoenbergChief Medical Officer | sold | 5,222at $27.30 | 8 Jun 2026filed 9 Jun 2026 |
| Mark SchoenbergChief Medical Officer | sold | 10,000at $30.00 | 8 May 2026filed 11 May 2026 |
| Mark SchoenbergChief Medical Officer | sold | 1,844at $19.69 | 3 Feb 2026filed 4 Feb 2026 |
| Mark SchoenbergChief Medical Officer | sold | 1,843at $19.69 | 3 Feb 2026filed 4 Feb 2026 |
| Mark SchoenbergChief Medical Officer | sold | 3,686at $19.69 | 3 Feb 2026filed 4 Feb 2026 |
| Jason Drew SmithGeneral Counsel | sold | 2,654at $19.69 | 3 Feb 2026filed 11 Feb 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| RTW INVESTMENTS, LPunchanged · filed 14 Aug 2026 | 4,543,895$167.2M | 00.0% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 3,201,461$117.8M | +355,894+12.5% |
| MORGAN STANLEYadded · filed 13 Aug 2026 | 2,576,363$94.8M | +16,325+0.6% |
| Kynam Capital Management, LPadded · filed 14 Aug 2026 | 2,434,207$89.6M | +186,814+8.3% |
| Jefferies Financial Group Inc.unchanged · filed 17 Aug 2026 | 2,199,652$80.9M | 00.0% |
| AMERICAN CENTURY COMPANIES INCadded · filed 12 Aug 2026 | 1,685,719$62.0M | +48,149+2.9% |
| ACORN CAPITAL ADVISORS, LLCunchanged · filed 14 Aug 2026 | 1,673,420$61.6M | 00.0% |
| Point72 Asset Management, L.P.new · filed 14 Aug 2026 | 1,525,549$56.1M | +1,525,549 |
| FRONTIER CAPITAL MANAGEMENT CO LLCadded · filed 14 Aug 2026 | 1,508,547$55.5M | +194,435+14.8% |
| Opaleye Management Inc.added · filed 14 Aug 2026 | 1,439,996$53.0M | +9,996+0.7% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.